Author: BusinessWire
Experian Accelerates Identity and Activation Capabilities With Acquisition of Audigent
December 04 – COSTA MESA, Calif.–(BUSINESS WIRE)–Experian® — the global data and technology company — announced today it has acquired Audigent, a leading data activation and identity platform in the advertising industry. The acquisition further expands Experian’s deeply integrated marketing data and identity capabilities in the advertising ecosystem. With the addition of Audigent’s combined first-party publisher […]
The post Experian Accelerates Identity and Activation Capabilities With Acquisition of Audigent appeared first on Ben Franklin Technology Partners.
... Read More >AmorSui Announces $3.5M Seed Funding to Revolutionize Sustainable Medical Supplies
NEW YORK–(BUSINESS WIRE)–AmorSui, a modern personal protective equipment (PPE) brand dedicated to protecting people and the planet, announced today that it has raised $3.5 million in seed funding. AmorSui’s mission is to make PPE more sustainable, inclusive, and affordable over time, setting a new benchmark of quality in the medical supply sector. Investors include Gold […]
The post AmorSui Announces $3.5M Seed Funding to Revolutionize Sustainable Medical Supplies appeared first on Ben Franklin Technology Partners.
... Read More >Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation For NTX-001 And Provides Update On The Advancements Of NTX-001 For The Treatment Of Peripheral Nerve Injury Requiring Repair
CHESTERBROOK, Pa.–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking […]
The post Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation For NTX-001 And Provides Update On The Advancements Of NTX-001 For The Treatment Of Peripheral Nerve Injury Requiring Repair appeared first on Ben Franklin Technology Partners.
... Read More >Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing
Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing. The funding round is being led by 8VC and DCVC Bio. To date, Samsung Life Science Fund (created by Samsung […]
The post Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing appeared first on Ben Franklin Technology Partners.
... Read More >Cagent Vascular Raises $30 Million Series C Financing
Funds will be used to accelerate US market adoption and to expand the product portfolio of the first and only Serration Angioplasty Technology Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M. U.S. Venture Partners (USVP), led the round. Participation included new […]
The post Cagent Vascular Raises $30 Million Series C Financing appeared first on Ben Franklin Technology Partners.
... Read More >SAIL Fusion Announces First Implantations Of Its BowTie™ Sacroiliac Fusion System
SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon AO principles, today announced that it has conducted the first implantations of its novel BowTie SI Fusion System. The surgeries began on October 14th and were conducted by Dr. Peter Whang, Associate Professor of Orthopaedics […]
The post SAIL Fusion Announces First Implantations Of Its BowTie™ Sacroiliac Fusion System appeared first on Ben Franklin Technology Partners.
... Read More >Cagent Vascular Announces Initial RECOIL Study Results: Serranator Demonstrates 49% Less Recoil Than POBA In BTK Arteries
Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study. This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA). The study results demonstrated that lesions treated using […]
The post Cagent Vascular Announces Initial RECOIL Study Results: Serranator Demonstrates 49% Less Recoil Than POBA In BTK Arteries appeared first on Ben Franklin Technology Partners.
... Read More >CampusESP Welcomes Customer 300: University Of Kentucky
CampusESP, the leading provider of technology solutions that help colleges and universities engage parents and families, announced today that it signed its 300th customer, the University of Kentucky. Founded in 2016, CampusESP has built a reputation as the go-to leader in parent and family engagement solutions, leading with the message that a strong family […]
The post CampusESP Welcomes Customer 300: University Of Kentucky appeared first on Ben Franklin Technology Partners.
... Read More >